| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors LV Sequist, BA Waltman, D Dias-Santagata, S Digumarthy, AB Turke, ... Science translational medicine 3 (75), 75ra26-75ra26, 2011 | 3650 | 2011 |
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ... Cancer cell 17 (1), 77-88, 2010 | 1224 | 2010 |
| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1100 | 2016 |
| EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib RB Corcoran, H Ebi, AB Turke, EM Coffee, M Nishino, AP Cogdill, ... Cancer discovery 2 (3), 227-235, 2012 | 1100 | 2012 |
| Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, ... The oncologist 17 (1), 72-79, 2012 | 810 | 2012 |
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ... Clinical cancer research 19 (15), 4273-4281, 2013 | 635 | 2013 |
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma C Montagut, SV Sharma, T Shioda, U McDermott, M Ulman, LE Ulkus, ... Cancer research 68 (12), 4853-4861, 2008 | 616 | 2008 |
| Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 K Ohashi, LV Sequist, ME Arcila, T Moran, J Chmielecki, YL Lin, Y Pan, ... Proceedings of the National Academy of Sciences 109 (31), E2127-E2133, 2012 | 509 | 2012 |
| Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor Z Piotrowska, MJ Niederst, CA Karlovich, HA Wakelee, JW Neal, ... Cancer discovery 5 (7), 713-722, 2015 | 501 | 2015 |
| Nedd8 on cullin: building an expressway to protein destruction ZQ Pan, A Kentsis, DC Dias, K Yamoah, K Wu Oncogene 23 (11), 1985-1997, 2004 | 491 | 2004 |
| Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011 | 470 | 2011 |
| Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas PK Brastianos, A Taylor-Weiner, PE Manley, RT Jones, D Dias-Santagata, ... Nature genetics 46 (2), 161-165, 2014 | 457 | 2014 |
| Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience LM Sholl, DL Aisner, M Varella-Garcia, LD Berry, D Dias-Santagata, ... Journal of thoracic oncology 10 (5), 768-777, 2015 | 442 | 2015 |
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation RB Corcoran, D Dias-Santagata, K Bergethon, AJ Iafrate, J Settleman, ... Science signaling 3 (149), ra84-ra84, 2010 | 421 | 2010 |
| Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ... EMBO molecular medicine 2 (5), 146-158, 2010 | 412 | 2010 |
| Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models RB Corcoran, KA Cheng, AN Hata, AC Faber, H Ebi, EM Coffee, ... Cancer cell 23 (1), 121-128, 2013 | 405 | 2013 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 402 | 2019 |
| Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for … Z Piotrowska, H Isozaki, JK Lennerz, JF Gainor, IT Lennes, VW Zhu, ... Cancer discovery 8 (12), 1529-1539, 2018 | 384 | 2018 |
| The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ... Cell 158 (3), 564-578, 2014 | 380 | 2014 |
| BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ... PloS one 6 (3), e17948, 2011 | 360 | 2011 |
